Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.36 (hyaluronidase)
 4,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Adenocarcinomas of or in lung that clinically and pathologically mimic diffuse pleural mesotheliomas are rare. We reviewed selected clinical and pathologic features of 15 autopsy/surgical cases previously reported in the medical literature and of 15 additional cases from the files of the Armed Forces Institute of Pathology (AFIP). Ninety percent of the patients were men. The median age was 61 years. Sixty-three percent of the patients smoked, 17% of them had possible or definite occupational exposure to asbestos, and one patient had microscopically proven asbestosis. Most patients had chest pain, shortness of breath, or cough, and had unilateral pleural effusion in the chest x-ray. At thoracotomy or at autopsy, numerous nodules, plaques, or a continuous rind of tumor was present over the pleural surface. Microscopically, the tumors showed simplified glands, nests, cords, papillary, tubulopapillary or biphasic patterns of growth. The neoplasms contained mucin that stained with diastase-predigested periodic acid-Schiff (PAS), mucicarmine, and alcian blue (with or without hyaluronidase predigestion). All patients died with/of tumor, with a mean survival of 4.7 months for those reported in the medical literature and of 7 months for those in the AFIP files. These adenocarcinomas therefore mimic pleural mesothelioma not only in their clinical and gross and microscopic appearance, but also in their prognosis.
 ...
PMID:Pseudomesotheliomatous adenocarcinoma: a reappraisal. 160 54

79 patients with suspected myocardial infarction entered a randomised trial to establish the safety of early intravenous administration of a highly purified hyaluronidase preparation (GL enzyme) and to assess its effects on eventual infarct size as measured by electrocardiographic, enzymatic, and scintigraphic criteria. Of the 71 patients with infarction, 35 received GL enzyme and 36 placebo within 6 h of the onset of chest pain. GL enzyme injected into a peripheral vein produced no adverse changes in the clinical, haemodynamic, biochemical, or haematological variables studied. GL enzyme reduced precordial electrocardiographic indices of infarct size as reflected by a diminution (p less than 0.02) in the degree of both R wave loss and Q wave development. In addition, the number of leads developing pathological Q waves (N delta Q greater than or equal to 2), a sign of progression from ischaemia to necrosis, was reduced (p less than 0.05) after GL enzyme treatment. However, there were no significant differences in infarct size as measured by cumulative creatine kinase MB isoenzyme release or technetium-99m pyrophosphate scintigraphic infarct area, or in clinical outcome during the hospital stay. Interpretation of the enzymatic and scintigraphic data was complicated by chance bias in pre-treatment randomisation which resulted in more (p less than 0.05) patients with severe haemodynamic impairment (and hence probably larger infarct sizes) entering the GL enzyme group. Nonetheless, a favourable effect of GL enzyme on infarct size was demonstrated by precordial electrocardiographic QRS mapping, here each patient acts as his or her own control.
 ...
PMID:Effects of early administration of a highly purified hyaluronidase preparation (GL enzyme) on myocardial infarct size. 612 98

The malignant pleural mesothelioma is a rare tumor of the general population. The exposure of asbestos still remains the main factor of risk, found in 72 to 95 % of the patients. The diagnosis is difficult. The symptoms are poor, with most often chronic pleural effusion, with dyspnea, associated with localized chest pain. The histological diagnosis is made on thoracoscopic biopsy. Analysis of the histochemical profile (PAS-D, hyaluronidase, vimentine), the use of immunochemistry (CEA, keratines), and electron microscopy can facilitate the making of the diagnosis. There is 3 different entities of malignant mesothelioma: the epithelial type, mixed, and sarcomatous. The tagging is based on thoracic scanner, to determinate the extent of the tumor, her relation with the local structures, and the possible involvement of the mediastinal lymph nodes. There is several staging systems, the Butchart's staging classification, and most recently the IMIG (International Mesothelioma Interest Group) classification. The significant prognostic factors, in multivariate analysis are: the stage of the disease, the histologic type, and the performance status of the patient. The current therapeutic maneuvers (surgery, chemotherapy, radiotherapy) did not show significant improvement of the survival. The radical surgery, like pleuropneumonectomy, should be consider only for patients with an early stage of the disease. The chemotherapy, with single agent or in combination, still remains disappointing, with objective response rates between 20 and 30 %, in best cases. The curative radiotherapy is limited by the importance of the target-volume, and the proximity of critical organ (lung, heart). Only the preventive radiotherapy, on scars, niddle or surgical tracts is recommended. Immunotherapy, by systemic or intracavitary administration, remains limited because of the toxicity, especially infection. All of the therapeutic maneuvers should be proposed in clinical trials.
 ...
PMID:[Malignant pleural mesothelioma]. 1058 73